ACR-6840
/ Acrivon Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 08, 2026
ACR-6840, a potential first-in-class CDK11 inhibitor, nominated as the next development candidate from company’s AP3-driven cell cycle program, with several promising back-up series also identified
(Acrivon Press Release)
- "IND submission anticipated in the fourth quarter of 2026."
IND • New molecule • Oncology
1 to 1
Of
1
Go to page
1